Actualizing new modalities for drug product development, manufacturing and packaging to create resilient and affordable supply of our most critical use pharmaceuticals.
As foundational elements in the delivery of effective care to patients across the healthcare system, shortages of GSI drugs ‘generate substantial adverse impacts through treatment delays, the use of inferior alternatives, and an increased risk of medication errors.’
Non-functioning market dynamics are the root cause of GSI shortage: users across the healthcare system prioritize GSI supply only on price, as they neither observe quality directly nor carry the full burden of patient harm resulting from shortages.
Price pressure & a lack of ability on the part of regulators to strictly enforce standards incentivize manufacturers to compromise their commitment to good manufacturing practices.
When quality issues come to light, recalls and production interruptions lead to shortages. Patients suffer, and a public health crisis results due to the lack of sufficiently positioned manufacturing infrastructure and proper supply chain management.
Reducing dependencies that have been built over decades will be a complicated and arduous process. All the same, it is a process that must be undertaken in the interest of being able to assure a satisfactory supply of critical acute drugs.
The prevailing market dynamics, marred by shortsighted incentives, prove fragile during external shocks. COVID-19 exemplifies this vulnerability. Furthermore, the growing tendency of nation-states to strategically exploit production concentration heightens the risk of deliberate supply disruptions. Rethinking these dynamics is paramount for a resilient and secure supply chain.
Keep up with the rapidly evolving situation via the CIDRAP Special Project: Resilient Drug Supply.
Our strategy for offering a unique portfolio of ready-to-use or ready-to-mix IV bag products for IVMA stems from the team's extensive market experience. Due to the limited development capabilities with GMP bag fill-and-finish capacity, Xceed BioPharma will provide innovative CDMO services for partners seeking to bring their solutions to market.
Our strategy for offering a unique portfolio of ready-to-use or ready-to-mix IV bag products for IVMA stems from the team's extensive market experience. Due to the limited development capabilities with GMP bag fill-and-finish capacity, Xceed BioPharma will provide innovative CDMO services for partners seeking to bring their solutions to market.
Iteratively refining drug development, manufacturing, and supply chain processes enhances pharmaceutical resilience and affordability through strategic partnerships and sustainable innovation.
Innovative development prioritizes cutting-edge tech, expert collaboration, and agile prototyping to rapidly shape pharmaceutical concepts into viable solutions, advancing critical medication refinement
Efforts aim to boost affordable pharmaceutical production for prompt patient access. Quality is prioritized with strict testing and compliance, supported by sustainability and high standards.
The shortage of active pharmaceutical ingredients (APIs) presents a substantial hurdle in the pharmaceutical sector, directly impacting patients' access to essential medications. This challenge stems from overreliance on a limited number of suppliers, complex manufacturing processes, regulatory barriers, and the intricate nature of global supply chains.
Addressing the API shortage necessitates innovative strategies. Embracing diverse sourcing approaches from multiple suppliers, adopting cutting-edge manufacturing technologies, streamlining regulatory frameworks, and fostering collaborative efforts are imperative. These transformative measures aim to ensure a consistent and uninterrupted supply of vital medicines, crucial for promoting public health.
We are deeply committed to offer expertise, and scalable solutions to pharmaceutical innovators. Our goal is to revolutionize drug development and supply, ensuring reliable access to vital medications.
© 2024 Xceed BioPharma. All Rights Reserved
Actualizing new modalities for drug product development, manufacturing and packaging to create resilient and affordable supply of our most critical use pharmaceuticals.
As foundational elements in the delivery of effective care to patients across the healthcare system, shortages of GSI drugs ‘generate substantial adverse impacts through treatment delays, the use of inferior alternatives, and an increased risk of medication errors.’
Non-functioning market dynamics are the root cause of GSI shortage: users across the healthcare system prioritize GSI supply only on price, as they neither observe quality directly nor carry the full burden of patient harm resulting from shortages.
Price pressure & a lack of ability on the part of regulators to strictly enforce standards incentivize manufacturers to compromise their commitment to good manufacturing practices.
When quality issues come to light, recalls and production interruptions lead to shortages. Patients suffer, and a public health crisis results due to the lack of sufficiently positioned manufacturing infrastructure and proper supply chain management.
Reducing dependencies that have been built over decades will be a complicated and arduous process. All the same, it is a process that must be undertaken in the interest of being able to assure a satisfactory supply of critical acute drugs.
The prevailing market dynamics, marred by shortsighted incentives, prove fragile during external shocks. COVID-19 exemplifies this vulnerability. Furthermore, the growing tendency of nation-states to strategically exploit production concentration heightens the risk of deliberate supply disruptions. Rethinking these dynamics is paramount for a resilient and secure supply chain.
Keep up with the rapidly evolving situation via the CIDRAP Special Project: Resilient Drug Supply.
Our strategy for offering a unique portfolio of ready-to-use or ready-to-mix IV bag products for IVMA stems from the team's extensive market experience. Due to the limited development capabilities with GMP bag fill-and-finish capacity, Xceed BioPharma will provide innovative CDMO services for partners seeking to bring their solutions to market.
Our strategy for offering a unique portfolio of ready-to-use or ready-to-mix IV bag products for IVMA stems from the team's extensive market experience. Due to the limited development capabilities with GMP bag fill-and-finish capacity, Xceed BioPharma will provide innovative CDMO services for partners seeking to bring their solutions to market.
Iteratively refining drug development, manufacturing, and supply chain processes enhances pharmaceutical resilience and affordability through strategic partnerships and sustainable innovation.
Innovative development prioritizes cutting-edge tech, expert collaboration, and agile prototyping to rapidly shape pharmaceutical concepts into viable solutions, advancing critical medication refinement
Efforts aim to boost affordable pharmaceutical production for prompt patient access. Quality is prioritized with strict testing and compliance, supported by sustainability and high standards.
The shortage of active pharmaceutical ingredients (APIs) presents a substantial hurdle in the pharmaceutical sector, directly impacting patients' access to essential medications. This challenge stems from overreliance on a limited number of suppliers, complex manufacturing processes, regulatory barriers, and the intricate nature of global supply chains.
Addressing the API shortage necessitates innovative strategies. Embracing diverse sourcing approaches from multiple suppliers, adopting cutting-edge manufacturing technologies, streamlining regulatory frameworks, and fostering collaborative efforts are imperative. These transformative measures aim to ensure a consistent and uninterrupted supply of vital medicines, crucial for promoting public health.
We are deeply committed to offer expertise, and scalable solutions to pharmaceutical innovators. Our goal is to revolutionize drug development and supply, ensuring reliable access to vital medications.
© 2024 Xceed BioPharma. All Rights Reserved
